who runs it
organizations running this strategy · 4
what it looks like in practice
activities of orgs running this strategy
A sample of programmatic activities from the orgs above. These are what the strategy looks like on the ground.
- Collaborating on Clinical Decision Support Programs AZCERTresearchAZCERT participates in multi-stakeholder collaborations to develop and disseminate clinical decision support programs, such as for QTc Risk Score, to enhance medication safety.
- Collaborating on Clinical Decision Support Programs AZCERTresearchAZCERT participates in multi-stakeholder collaborations to develop and disseminate clinical decision support programs, such as for QTc Risk Score, to enhance medication safety.
- Conduct drug safety surveillance AZCERTresearchPerforms active and passive surveillance of thousands of prescription drugs in the U.S. to assess QT prolongation risk and inform updates to the QTdrugs List.
- Conduct drug safety surveillance and literature review AZCERTresearchPerforms active and passive surveillance of thousands of prescription drugs available in the U.S. to assess associations with QT prolongation, using scientific literature, case reports, label changes, and clinical studies to inform safety evaluations.
- Conduct scientific research and publish findings AZCERTresearchAuthors peer-reviewed articles and expert opinions on drug safety, cardiovascular pharmacology, and regulatory science in journals such as Nature Reviews of Cardiology and Annual Review of Pharmacology and Toxicology. Topics include QT prolongation, drug regulation history, and medication risk assessment.
- Curate and update evidence-based drug safety lists AZCERTresearchRegularly evaluates and updates the QTdrugs List and the List of Drugs to Avoid in patients with Congenital Long QT Syndrome (cLQTS) based on scientific evidence reviewed by AZCERT's Scientific Review Committee. Updates include adding, removing, or reclassifying drugs according to their risk of QT prolongation and torsades de pointes (TdP).
- Curate and update evidence-based drug safety lists AZCERTresearchRegularly evaluates and updates the QTdrugs List and the List of Drugs to Avoid in patients with Congenital Long QT Syndrome (cLQTS) based on scientific evidence reviewed by AZCERT's Scientific Review Committee. This includes adding, removing, or reclassifying drugs according to their risk of QT prolongation and torsades de pointes (TdP).
- Develop and validate clinical decision support tools AZCERTresearchDesigns, validates, and disseminates MedSafetyScan, an online QT/torsades de pointes patient risk assessment tool. The tool’s risk score model has been scientifically validated in psychiatric inpatient populations and through multi-stakeholder collaborations to support clinical decision-making.
- Develop and validate clinical decision support tools AZCERTresearchDesigns, validates, and disseminates MedSafetyScan, an online QT/torsades de pointes patient risk assessment tool. The tool’s risk score model has been validated in peer-reviewed studies, including in psychiatric inpatient populations, and was developed through multi-stakeholder collaboration.
- Developing and Validating MedSafetyScan AZCERTresearchAZCERT developed and validated MedSafetyScan, an online tool for assessing patient risk of QT prolongation and torsades de pointes, with its efficacy and accuracy confirmed through scientific studies in psychiatric inpatient populations.
- Developing and Validating MedSafetyScan AZCERTresearchAZCERT developed and validated MedSafetyScan, an online tool for assessing patient risk of QT/torsades de pointes, with its efficacy and accuracy confirmed through scientific studies in psychiatric inpatient populations.
- Distribute drug safety information via CredibleMeds platform AZCERTdirect serviceMaintains and provides access to the QTdrugs List and related resources through the CredibleMeds.org website and mobile applications (iOS and Android), available in five languages, with visual icons indicating drug risk categories.
- Distribute educational materials on medication safety AZCERTdirect serviceProvides downloadable lists of medications with potential heart rhythm risks, articles for public reading and bookmarking, and information on monoclonal antibody treatments and COVID-19 vaccines for high-risk populations.
- Enable personalized medication tracking and user engagement AZCERTdirect serviceAllows users to create personal medication logs, submit questions to AZCERT’s founder Dr. Ray Woosley, and receive email notifications when the QTdrugs List is updated.
- Evaluating Specific Drugs for QT Prolongation AZCERTresearchAZCERT's Scientific Review Committee evaluates specific drugs, such as Opipramol, Revumenib, Sitafloxacin, Bilastine, Gepotidacin, Dordaviprone, Triclabendazole, Ziftomenib, Milsaperidone, Cinacalcet, Pacritinib, Vernakalant, Fexinidazole, Benzonatate, Macimorelin, Dexmedetomidine, Pralsetinib, Adagrasib, Tebentafusp, Remdesivir, Ponesimod, and Voclosporin, for their association with QT prolongation and potential for Torsades de Pointes (TdP).
- Issue public drug safety alerts and recalls AZCERTresearchIssues warnings about specific manufacturing lots of medicines recalled due to unacceptable levels of carcinogenic chemicals, based on safety evaluations.
- Issue public safety alerts on contaminated medications AZCERTresearchIssues warnings about specific manufacturing lots of medicines recalled due to unacceptable levels of carcinogenic chemicals.
- Maintaining and Updating the QTdrugs List AZCERTresearchAZCERT maintains and regularly updates the QTdrugs List, a comprehensive database of medications associated with QT prolongation and potential heart rhythm disturbances, based on scientific evidence reviewed by its Scientific Review Committee through active and passive surveillance of data for thousands of prescription drugs.